港股異動 | 醫藥股集體走強 2021年國家醫保目錄准入談判今日啟動
格隆匯11月9日丨港A醫藥股今日集體走強,其中港股藥明生物漲10%,康龍化成漲7%,昭衍新藥漲6%,泰格醫藥漲4%,藥明康德漲3%,金斯瑞漲2%;A股康龍化成漲9%,南微醫學,天宇股份漲8%,貝達藥業漲6%,山東藥玻漲5%,恆瑞醫藥漲0.87%。11月9日,2021年國家醫保目錄准入談判將正式啟動,根據國家醫保局此前公佈的《2021年國家醫保藥品目錄調整通過形式審查的申報藥品名單》,本次醫保談判將涉及恆瑞醫藥、百濟神州、榮昌生物、羅氏、輝瑞等多家知名企業的多個重要品種,如 PD-1 單抗、BTK 抑制劑、PARP 抑制劑等,雙抗、ADC、CAR-T 等新型療法也有望參與。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.